Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors.
Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, Darland DC, Young MJ, D'Amore PA. · 2008
Read Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors. by Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, Darland DC, Young MJ, D'Amore PA. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2571983.txt.
Introduction
Saint-Geniez and colleagues asked in 2008 whether the adult retina needs its own supply of VEGF, a growth factor famous for driving blood vessel growth. Anti-VEGF drugs are widely injected into eyes and given for cancer, yet VEGF also appears to act on non-vessel cells. Using reporter mice and staining, the team showed the factor is made across the adult mouse retina. Its receptor sits strongly on Müller cells and photoreceptors, the light-sensing cells.
Blocking VEGF throughout the body for two weeks left retinal vessels untouched but increased death of retinal neurons. By four weeks the cell layers had thinned and electrical responses of the retina had declined. Silencing VEGF in cultured Müller cells also threatened their survival. The authors caution that anti-VEGF therapy may carry retinal risks.
Catalog record
| CREATOR | Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, Darland DC, Young MJ, D'Amore PA. |
|---|---|
| YEAR | 2008 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 68 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Müller Cells and Photoreceptors By Magali Saint-Geniez, Arindel S R Maharaj, Tony E Walshe, Budd A Tucker, Eiichi Sekiyama, Tomoki Kurihara, Diane C Darland, Michael J Young, Patricia A D'Amore, Tailoi Chan-Ling Published in: PLoS ONE DOI: 10.1371/journal.pone.0003554 ABSTRACT Abstract Background Vascular endothelial growth factor (VEGF) is well known for its role in normal and pathologic neovascularization. However, a growing body of evidence indicates that VEGF also acts on non-vascular cells, both developmentally as well as in the adult. In light of the widespread use of systemic and intraocular anti-VEGF therapies for the treatment of angiogenesis associated with tumor growth and wet macular degeneration, systematic investigation of the role of VEGF in the adult retina is critical. Methods and Findings Using immunohistochemistry and Lac-Z reporter mouse lines, we report that VEGF is produced by various cells in the adult mouse retina and that VEGFR2, the primary signaling receptor, is also widely expressed, with strong expression by Müller cells and photoreceptors. Systemic neutralization of VEGF was accomplished in mice by adenoviral expression of sFlt1. After 14 days of VEGF neutralization, there was no effect on the inner and outer retina vasculature, but a significant increase in apoptosis of cells in the inner and outer nuclear layers. By four weeks, the increase in neural cell death was associated with reduced thickness of the inner and outer nuclear layers and a decline in retinal function as measured by electroretinograms. siRNA-based suppression of VEGF expression in a Müller cell line in vitro supports the existence of an autocrine role for VEGF in Müller cell survival. Similarly, the addition of exogenous VEGF to freshly isolated photoreceptor cells and outer-nuclear-layer explants demonstrated VEGF to be highly neuroprotective. Conclusions These results indicate an important role for endogenous VEGF in the maintenance and function of adult retina neuronal cells and indicate that anti-VEGF therapies should be administered with caution. INTRODUCTION The retina is one of the body's most metabolically demanding tissues. To ensure adequate nutrient and oxygen delivery, the retina is supplied by two independent vascular beds, the inner retinal vasculature and outer choroidal circulation. These vascular beds have distinct morphologic properties; the inner retinal vasculature is the site of a blood-tissue barrier and is characterized by highly impermeable vessels, whereas the choriocapillaris consists of a highly fenestrated capillary plexus. Vascularization of the retina (reviewed in [1]) occurs late in gestation and is restricted to the inner retina. During development, vascular endothelial growth factor (VEGF) is expressed by astrocytes in the retinal ganglion cell layer (GCL), by cells of inner nuclear layer (INL), Müller cells, and retinal pigment epithelial cells (RPE) [2], [3]. Targeted deletion of VEGF in the RPE results in failure of choroidal development and loss of visual function [4]. Whereas formation of the choriocapillaris appears to be independent of hypoxia [4], formation of the inner retinal vasculature requires induction of the hypoxia inducible factor-1β [5]. Hyperoxia during retinal development suppresses VEGF production resulting in reduced vascular development [5], as is seen in retinopathy of prematurity [6]. Furthermore, normal retinal vascularization requires the coordinated expression of specific VEGF isoforms, which differ in their solubility and binding to VEGF receptors [7]. In addition to its role in developmental retinal vascularization, VEGF is upregulated in several ocular pathologies, including wet age related macular degeneration (AMD) [8] and proliferative diabetic retinopathy [9]. In AMD, injury to the RPE is thought to result in increased VEGF expression. Coupled with damage to Bruch's membrane, this leads to proliferation of choroidal vessels, which invade the subretinal space [10]. In proliferative diabetic retinopathy, the neovascularization that arises from the inner retina is mediated by hypoxia-induced VEGF (reviewed in [11]). The involvement of VEGF in AMD has led to the Food and Drug Administration approval of two intraocular anti-VEGF drugs, pegaptanib sodium (Macugen, OSI/Eyetech Pharmaceuticals, NY) [12], an aptamer which was reported to inhibits only VEGF165, and ranibizumab (Lucentis, Genentech) [13], a Fab fragment of the humanized monoclonal VEGF antibody bevacizumab (Avastin, Genentech) which neutralizes all VEGF isoforms. While the role of VEGF in developmental and pathologic retinal vascularization is well understood, its function in the normal adult is unclear. We and others have previously reported that VEGF is expressed in the adult retina by RPE [3] as well as by neuronal and glial cells [14], [15], [16], [17]. Although initially thought to be endothelial-specific, VEGF has been shown to target a variety of non-vascular cells (reviewed in [18]) including, neural stem cells [19], ependymal cells [20] and neuronal cells of the central nervous system [21], [22]. In addition, VEGF neutralization in humans via intraocular injection of Macugen and Avastin is associated with an increased incidence of retinal tears [23], [24]. Similarly, preeclampsia, which is mediated in part by elevated circulating levels of a soluble form of VEGF receptor 1 called sFlt1 leading to systemic VEGF neutralization [25], is also associated with ocular symptoms including RPE lesions, choroidal ischemia and retinal detachments [26], [27]. Given the expression of VEGF and VEGF receptor 2 (VEGFR2) in the adult retina, and the constitutive activation of the receptor, we hypothesized that VEGF plays a role in maintenance and function of the adult retina. We report that, in addition to the choriocapillaris and retinal vasculature, VEGFR2 is expressed by adult photoreceptor cells and Müller cells. While systemic neutralization of VEGF in the mouse did not lead to detectable changes in retinal vascular perfusion or permeability, there was significant cell death in the INL and outer nuclear layer (ONL) as well as loss of visual function. A direct survival function for VEGF was demonstrated using a Müller cell line as well as primary photoreceptor cells and sheets. Taken together, these observations implicate VEGF in maintenance of the adult neural retina. RESULTS VEGF and VEGFR2 expression in adult retina We have previously shown that VEGF is expressed by embryonic and adult RPE [3]. To examine VEGF expression patterns in adult eye, we used mice heterozygous for the LacZ reporter gene with a nuclear localization signal under the control of the VEGF promoter (28). Here we show that VEGF is also expressed by cells in the GCL and INL in the adult mouse retina (Figure 1A, arrowheads and asterisks, respectively). To determine the identity of the cells expressing VEGF in the GCL, flat-mounted retinas from adult VEGF-LacZ mice [28] were co-labeled for lac-Z and for NG2, the chondroitin sulfate proteoglycan, as a pericyte marker [29]. There were two distinct populations of Lac-Z positive cells. One was pericytes, identified by their expression of NG2 and their characteristic abluminal association with the microvessels (Figure 1B arrowheads). The second population of VEGF-expressing cells in the innermost retinal layer were astrocytes (Figure 1B arrow and Figure S1). In the retina, astrocytes are characterized by cell bodies that are located in the intercapillary spaces but with processes closely associated with the microvessels. Immunohistochemical localization of the astrocyte marker, glial fibrillary acidic protein (GFAP) [30], on VEGF-LacZ adult retina confirmed this second VEGF expressing cell population to be astrocytes (Figure S1). This pattern of VEGF expression in the GCL is consistent with our previous observations in postnatal retinal development [2]. [Figure: VEGF signaling in